
    
      1. To describe the toxicity associated with this regimen in adult patients with newly
           diagnosed glioblastoma multiforme.

        2. To determine the duration of disease free survival and overall survival associated with
           this therapy.

        3. Evaluate thrombospondin 1 (TSP-1) and 2 (TSP-2) in tumor vs. corresponding normal tissue
           using quantitative real time Polymerase Chain Reaction (Q-RT-PCR).

        4. Determine the effect of ABT 510 on tumor permeability and tumor blood volume as measured
           by non-invasive Magnetic Resonance Imaging (MRI).
    
  